New Platform for Tuberculosis Treatment

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 123

Special Issue Editors


E-Mail Website
Guest Editor
LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, 2829-516 Caparica, Portugal
Interests: sustainable chemistry; ionic liquids; drug delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Departamento de Química, LAQV-REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2825-149 Caparica, Portugal
Interests: sustainable chemistry; ionic liquids; catalysis; material science; responsive materials; energy; pharmaceuticals
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Chemistry Institute, LACASO—Laboratory of Catalysis and Organic Synthesis, Federal University of Rio de Janeiro, Rio de Janeiro 21941909, Brazil
Interests: organic synthesis; fluorinated molecules; medicinal chemistry; infectious diseases; homogeneous catalysis; nanostructured materials

E-Mail Website
Guest Editor
Chemistry Institute, LACASO—Laboratory of Catalysis and Organic Synthesis, Federal University of Rio de Janeiro, Rio de Janeiro 21941909, Brazil
Interests: drug discovery; molecular docking; molecular dynamics simulation; medicinal chemistry; machine learning

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “New Platform for Tuberculosis Therapy”, aims to explore and discuss the latest advancements in the development of novel drug delivery systems and formulations for the treatment of tuberculosis (TB). TB is a major global health problem, and the need for more effective and safer anti-TB drugs is urgent. Traditional treatment regimens are lengthy and associated with severe side effects, leading to poor patient compliance and the emergence of drug-resistant TB strains.

The main objective of this Special Issue is to provide a platform for researchers and scientists to share their findings and insights on the development of new drug delivery systems and formulations for anti-TB drugs. It will cover topics such as the design and development of novel drug carriers, the use of nanotechnology in drug delivery, and the enhancement of drug bioavailability and targeting.

Potential topics to be covered include, but are not limited to, the following:

  • Development of novel and effective antimycobacterial agents;
  • Innovative drug delivery systems for TB treatment;
  • Emerging molecular targets for TB drug discovery;
  • Host-targeted therapies.

By collating the latest research and advancements in this field, this Special Issue aims to promote collaboration and foster innovation in the development of a new platform for tuberculosis therapy.

Dr. Željko Petrovski
Dr. Luis Cobra Branco
Dr. Raoni Schroeder Borges Gonçalves
Dr. Camilo Henrique da Silva Lima
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tuberculosis
  • anti-TB drugs
  • drug delivery systems
  • nanotechnology
  • bioavailability
  • targeting

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop